We publish news of technology innovations, investment opportunities, together with updates from spinout & startup companies and licensees
Caristo's Frank Cheng speaks with OUI on transforming heart disease diagnostics, the evolution of Oxford, and the future of one of Oxford's most exciting companies.
Beacon Therapeutics, a pioneering new biotech company, has launched with a mission to restore and improve the vision of patients with retinal diseases. The company is one of the most ambitious spinouts the University has been involved in to date, starting out with an impressive £96 million ($118.5m) in funding, the biggest launch for any company including an Oxford spin-out programme.
Take a glimpse into the future with startups emerging from OUI’s incubator.
The 2023 Spotlight on Spinouts report once again underlines Oxford’s leading position in spinout creation. The report underlines Oxford Science Enterprises’ positive impact on Oxford’s spinout community, while investments into Oxford spinouts remain high, despite UK-wide downturn.
The University of Oxford partners with top universities and investors to agree terms which will greatly increase the UK’s capacity to turn world-leading research into spinouts that will generate economic growth and societal impact.
FluoRok is revolutionising the production of fluorochemicals with their HF-free fluorination processes that are safer, more efficient, and environmentally conscious. Led by Moissan-prize winner Professor Véronique Gouverneur FRS and CEO Dr Gabriele Pupo, the team is building on over two decades of research to provide a solution to the challenges of the current production process.
Discover 10 Oxford University companies with their sights firmly set on defining the future.
Quantum Motion, an Oxford firm making quantum computers on silicon a reality, is riding high after a £42m funding round. To find out more, OUI's Gregg Bayes-Brown spoke with QM’s CEO James Palles-Dimmock.
